THIRD QTR SALES UP AT INTERPHARM
The Israeli pharmaceutical manufacturer Interpharm Laboratories posted sales of $9.1 million for the third quarter of 1991, up 31% on the like, year-earlier period. Net income for the quarter ended September 30 rose 7.7% to $1.5 million or $0.25 per share.
The increase was attributed primarily to an increase in sales of Frone, its native beta interferon. The product made sales of $8.9 million, compared with $6.1 million in the third quarter of 1990. Sales of human growth hormone amounted to $0.3 million, down 66%.
Gross R&D expenditure rose 50% during the quarter to $1.7 million. Several scientists were added to Interpharm's R&D department, as it continues to emphasize its vigorous development effort. The company continues to focus on the preparation of recombinant beta interferon (R-Frone), along with other developments, such as developing genetic engineering technologies for the production of cytokines and lymphokines, mainly interleukin-6.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze